Epicrispr Biotechnologies

The Epicrispr team is on the ground at #ESGCT2024 and excited to present 3 posters, including new data on a novel epigenetic modulator we developed for gene reactivation.     The ability to reactivate epigenetically silenced genes could open new avenues for #EpigeneticEditing therapies. And Epicrispr’s data show that by combining this modulator with our existing activators, the gene activation is incredibly robust.    Learn more about our ESGCT presentations in our press release: https://lnkd.in/ez6wiCP2   #biotechnology #EpigeneticEditing   #epicrispr 

We’ve developed a suite of super-small Cas molecules for Epicrispr’s #EpigeneticEditing therapies. And they’re not limited to just that application: As a new article by Revvity appearing in Technology Networks points out, smaller nucleases with better safety profiles and wider genomic reach could be beneficial across many types of genetic medicines.    Recent studies by our partners at Revvity find that our deactivated Cas ONYX (dCasONYX), combined with their Pin-point #baseediting system, can drive efficient base editing in vivo. Because dCasONYX doesn’t cut or nick the DNA, it sidesteps some safety issues with traditional Cas nucleases. And because dCasONYX is derived from archaea, an ancient type of microbe humans hardly ever encounter, people have exceptionally low pre-existing immunity.      Check out the article here, and if you’re attending #ESGCT2024 this week, stop by our posters to learn more about our hypercompact Cas proteins.    https://lnkd.in/eEnh9Bke    #epicrispr 

If you’re attending #ESGCT2024 next week, stop by Epicrispr’s posters to learn more about our hypercompact Cas proteins and our EPI-321 program.

This week Epicrispr scientific founder Lei (Stanley) Qi is a featured keynote speaker at AIChE - American Institute of Chemical Engineers International Conference on #CRISPR Technologies, alongside George Church and other luminaries. Stanley’s talk, on precision #EpigeneticEditing, details some of the pioneering science that formed the basis of our field-leading GEMS platform to create epigenetic editing therapies.     See the full conference agenda at https://lnkd.in/eR2Cdfmk      #biotechnology #genetherapy #CRISPR2024 #epicrispr #epigeneticediting

We’re excited to be at World Muscle Society’s #WMS2024 this week to present some of the robust preclinical data on EPI-321, our epigenetic editing candidate for the treatment of #FSHD. Our poster will be available here once the presentation concludes: https://lnkd.in/eFMKkJj5     #epicrispr #epigeneticediting  

Our Head of Strategy and Operations, Benson Cheng, PhD, will be on-site in Phoenix, AZ, for Alliance for Regenerative Medicine's #CGMesa24. Want to connect? Find him on the conference partnering system and set up a one-on-one meeting. 

There’s still time to schedule one-on-one meetings with our CEO, Amber Salzman, as she shares exciting updates at Oppenheimer & Co. Inc.'s Private Life Sciences Company Showcase on October 1 in New York. Please message us if you are interested in scheduling time to meet!    #EpigeneticEditing

#EpigeneticEditing is on 🔥! And for good reason: It holds the potential to change the expression of genes without changing the underlying DNA. Check out this article from Labiotech.eu featuring Epicrispr Biotechnologies as one of the leading innovators in this space: https://lnkd.in/enqj5ifA #biotechnology #epigenetics

It’s #MuscularDystrophyAwareness Month, an opportunity to shed light on the many types of muscular dystrophy that collectively affect millions of people worldwide. At Epicrispr we’re passionate about delivering a better treatment for facioscapulohumeral muscular dystrophy (FSHD) by leveraging #EpigeneticEditing to address the epigenetic causes of the disease. #CureFSHD #musculardystrophy

Our scientific founder Lei (Stanley) Qi and colleagues recently published an authoritative review of the field of #EpigeneticEditing in Cell Press. The article surveys today’s technologies for targeted epigenetic editing, and describes its next act: as an entirely new modality for the safe treatment of diseases that have few or no options for disease-modifying therapy today. Read in full here: https://lnkd.in/dCQBRHfN